Jazz Pharmaceuticals PLC JAZZ shares have traded up 45 percent in the last six months, and the Vetr community has downgraded the stock from 3.5 stars to 3 stars.
The stock is down about seven handles since its underwhelming first-quarter earnings report on May 9.
See how crowdsourced ratings can help predict the market?
Vetr members have given Jazz Pharma a Hold rating and $156.97 price target. This price target is lower than the $182.93 price target from Wall Street analysts. The company opened Tuesday around $149.
Of all Vetr raters, about 43 percent believe traders and investors should buy Jazz Pharma stock.
For Vetr’s full analysis of Jazz Pharma, go here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.